Response to Letter to the Editor

Main Article Content

Nigel S.B. Rawson

Keywords

Public reimbursement, off lable, prescription drugs

Abstract

Author's response to comments from Dr Lexchin's Letter to the Editor regarding our article.

Abstract 94 | pdf Downloads 13

References

1. Rawson NSB, Chhabra A. Public reimbursement of prescription drugs used for off-label indications in Ontario. J Popul Ther Clin Pharmacol 2018;25:e23-30.
2. Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinal conditions: recommendations report (May 2016). https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdf (accessed on: November 20, 2018).
3. Lexchin J. Editorial. J Popul Ther Clin Pharmacol 2018;25:e31-2.
4. Avastin Product Monograph (June 6, 2018). http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Avastin/Avastin_PM_E.pdf (accessed on: November 20, 2018).
5. Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res 2017;9:721-30.